
Zealand Pharma, a biotech firm publicly listed in Denmark, has been undergoing comprehensive structural changes since March.
Back then, the firm announced that future product sales, as well as late-stage programs, would happen with the help of strategic partnerships going forward. Changing things up at Zealand Pharma also meant that the firm initiated a 90% reduction to its workforce in the US – and in its home country of Denmark, staffing was also cut.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app